GRCE
Grace Therapeutics, Inc
$
3.035
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.090
Open
3.090
VWAP
3.03
Vol
14.54K
Mkt Cap
41.90M
Low
3.030
Amount
44.10K
EV/EBITDA(TTM)
--
Total Shares
13.83M
EV
21.90M
EV/OCF(TTM)
--
P/S(TTM)
--
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Show More
Valuation Metrics
The current forward P/E ratio for Grace Therapeutics, Inc (GRCE.O) is -3.22, compared to its 5-year average forward P/E of -3.16. For a more detailed relative valuation and DCF analysis to assess Grace Therapeutics, Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.16
Current PE
-3.22
Overvalued PE
-2.44
Undervalued PE
-3.87
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.23
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.95
Undervalued EV/EBITDA
-1.50
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
12.21
Current PS
3.00
Overvalued PS
33.05
Undervalued PS
-8.63
Financials
Annual
Quarterly
FY2026Q1
N/A
Total Revenue
FY2026Q1
YoY :
-37.74%
-3.09M
Operating Profit
FY2026Q1
YoY :
+28.47%
-3.36M
Net Income after Tax
FY2026Q1
YoY :
-12.50%
-0.21
EPS - Diluted
FY2026Q1
YoY :
-49.92%
-1.80M
Free Cash Flow
FY2026Q1
N/A
Gross Profit Margin - %
FY2026Q1
N/A
FCF Margin - %
FY2026Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
GRCE News & Events
Events Timeline
2025-11-13 (ET)
2025-11-13
08:09:00
Grace Therapeutics announces Q2 earnings per share of 6 cents compared to a loss of 30 cents last year.
2025-10-23 (ET)
2025-10-23
08:12:20
Grace Therapeutics raises $4M by exercising common warrants
2025-09-22 (ET)
2025-09-22
08:15:45
Grace Therapeutics reveals details of Phase 3 STRIVE-ON safety trial presentation
Sign Up For More Events
Sign Up For More Events
News
9.5
11-04NASDAQ.COMBiotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead
9.0
06-25NewsfilterGrace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
3.0
06-22NASDAQ.COMGRACE THERAPEUTICS Earnings Preview: Recent $GRCE Insider Trading, Hedge Fund Activity, and More
Sign Up For More News
People Also Watch
FAQ
What is Grace Therapeutics, Inc (GRCE) stock price today?
The current price of GRCE is 3.035 USD — it has increased 0.17 % in the last trading day.
What is Grace Therapeutics, Inc (GRCE)'s business?
What is the price predicton of GRCE Stock?
What is Grace Therapeutics, Inc (GRCE)'s revenue for the last quarter?
What is Grace Therapeutics, Inc (GRCE)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Grace Therapeutics, Inc (GRCE)'s fundamentals?
How many employees does Grace Therapeutics, Inc (GRCE). have?